Individual item analysis
MYELOPROLIFERATIVE NEOPLASM, TSS
Distribution of individual item scores at baseline was examined (Figure The majority of patients in SIMPLIFY‐1 and SIMPLIFY‐2 experienced stability or improvement (i.e., a change of at most one point or an improvement of at least two points, respectively, from baseline to Week 24) in both the overall and symptomatic populations (Figures Percent improved, stable, or declined/worsened on MPN‐SAF TSS items by treatment group in SIMPLIFY‐1 (A) overall and (B) symptomatic populations. MMB, momelotinib; MPN‐SAF, Myeloproliferative Neoplasm Symptom Assessment Form; RUX, ruxolitinib; TSS, total symptom score.Percent improved, stable, or declined/worsened on MPN‐SAF TSS items by treatment group in SIMPLIFY‐2 (A) overall and (B) symptomatic populations. BAT, best available therapy; MMB, momelotinib; MPN‐SAF, Myeloproliferative Neoplasm Symptom Assessment Form; RUX, ruxolitinib; TSS, total symptom score.Likelihood of improvement for the MPN‐SAF TSS items in the (A) SIMPLIFY‐1 overall population, (B) SIMPLIFY‐1 symptomatic population, (C) SIMPLIFY‐2 overall population, and (D) SIMPLIFY‐2 symptomatic population. BAT, best available therapy; MPN‐SAF, Myeloproliferative Neoplasm Symptom Assessment Form; TSS, total symptom score.